MRFF Funding Opportunities

Several funding opportunities are currently available under the MRFF, seeking to address a range of different diseases and issues in different health settings. They are presented in order of application closing date below.

Want to assist with assessing MRFF grants?
The Department of Health is currently seeking interest from a range of stakeholders to assist in MRFF grant review and assessment as a member of a Grant Assessment Committee. More information is available here.

Open for application now

Pancreatic Cancer

$12 million is available in grants of up to $2 million for research projects that:

Stream 1: develop, implement and/or validate therapeutic approaches (drug and/or non-drug) for improving the management of pain and symptoms in individuals with pancreatic cancer

Stream 2: promote Australian involvement in international collaborative investigator-initiated clinical trials testing the effectiveness of treatments (drug and/or non-drug) for pancreatic cancer through the establishment and coordination of clinical trials site/s in Australia.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 1: 24 August

Round 2:  23 November

Grant guidelines are available here.

2022 Mitochondrial Donation Pilot Program

Up to $15 million is available to support one research and innovation project for up to five years that conducts a pilot program, including a clinical trial, for the purposes of building the evidence base to determine the safety, efficacy and feasibility of implementing mitochondrial donation reproductive technology in clinical practice settings.

The intended outcomes are:

    • assisting women whose mitochondria would predispose their potential children to mitochondrial disease to have a biological child who does not inherit that predisposition
    • building a body of knowledge through research and ongoing monitoring of trial participants (including children born as a result of mitochondrial donation) to support future government policy decisions regarding broader implementation of mitochondrial donation reproductive technology in clinical practice in Australia.

This grant opportunity is being administered by the NHMRC and minimum data is due on 31 August. The guidelines are available on Grant Connect.

2022 National Critical Research Infrastructure Grant Opportunity

$73 million is available in grants of up to $10 million for research and innovation projects that align with the following streams:

Stream 1: Address an area of unmet need by promoting the development and implementation of new research methodologies or applications including ‘omics’-led approaches and enhanced infrastructure linkage strategies by supporting development and/or expansion of research enablers such as:

    • biobanks
    • tissue repositories
    • novel platforms
    • secure health data environments to create valuable research resources.

Stream 2: Develop and translate into practice:

    • digital therapeutics
    • artificial intelligence enabled health interventions and technologies (eg wearables integrated into clinical practice)
    • applications or other software for use in clinical practice.

Stream 3: Utilise co-investment with the research sector, state and territory governments and industry in significant critical research infrastructure (eg facilities and equipment) to support:

    • development of research capacity
    • capability and/or effectiveness in an area of need
    • easily accessible facilities and platforms for the wider research community, including within industry.

If applying under Stream 3, you must be part of a consortia and contribute at least 34% of project costs in cash.

This grant opportunity is administered on Business.gov.au and more information is available here.   Applications close on 7 September.

Medicine Use and Intervention by Pharmacists

The 2022 Quality, Safety and Effectiveness of Medicine Use and Medicine program will fund organisations to undertake research to support innovative approaches to improve the quality and cost effectiveness of preventive healthcare interventions.  Applications to all Streams must be pharmacist-led; i.e. the Chief Investigator A (CIA) must be a pharmacist.

Stream 1: assess the feasibility (including cost effectiveness, and acceptability by patients and prescribing health professionals) of pharmacogenomic interventions by community pharmacists designed to optimise medication prescription and use

Stream 2: assess the feasibility (including cost effectiveness, scalability, and acceptability by patients and prescribing health professionals) of pharmacogenomic interventions to optimise the prescription and use of medicines for treating patients with cancer (oncology and supportive care)

Stream 3: implement, validate, and cost approaches that involve community and hospital pharmacists collaborating to improve medication management at transition into the community

Stream 4: implement, validate, and cost approaches for pharmacist interventions in residential aged care using objective patient focused indicators.

Up to $6.5 million is available in total, with applications closing on 7 September. The grants are administered by the Business Grants Hub.  The Guidelines are available on Grant Connect here.

Multiple Sclerosis

$18 million is available for research projects that:

Stream 1: promote Australian involvement in international collaborative investigator-initiated clinical trials testing the effectiveness of vaccines for prevention of latent Epstein-Barr virus infection through the establishment and coordination of clinical trials site/s in Australia

Stream 2: clinical trials to accelerate the development or repurposing of therapeutic candidates (including antivirals) to treat Epstein-Barr virus for the purpose of preventing or treating conditions such as multiple sclerosis

Stream 3: characterise how immune responses to viral infections trigger autoimmune diseases including multiple sclerosis in some individuals to generate knowledge that supports risk stratification so identified individuals can employ strategies to reduce their chance of developing autoimmune disease

Stream 4: develop, implement and/or validate approaches for early intervention in individuals recovering from viral infections that aim to reduce the risk and/or severity of the long-term autoimmune consequences, including multiple sclerosis.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 3 and 4: 16 November 2022

Round 1 and 2: 25 January 2023

Grant guidelines are available here.

2022 International Clinical Trial Collaborations Grant Opportunity

A total of $12 million is available, with maximum grants of $3 million, over two separate rounds. Applications to this Grant Opportunity must propose a single clinical trial in Australia in collaboration with international counterparts which aims to:

    • give patients across Australia more access to clinical trials
    • show which treatments and medicines work best for patients
    • provide researchers with more opportunities to work with international colleagues to bring international trials to Australian patients
    • promote new approaches that support efficient and effective research.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 1: 20 July 2022 CLOSED

Round 2:  8 February 2023

Grant guidelines are available here.

Opening Soon

2022 MRFF Joint Transnational Call

The European Joint Programme on Rare Diseases (EJP RD) brings over 130 institutions from 35 countries together to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation. 

As part of the EJP RD, international organisations have joined forces to carry out a joint call for proposals for transnational cooperative research projects in the field of rare diseases. The list of participating funding organisations is listed on the EJP RD website. 

The joint call is published at the same time by the funding organisations in the respective countries and coordinated centrally by a Joint Call Secretariat (JCS). The JCS is based at the Institute of Health Carlos III (ISCIII, Spain). The respective national guidelines apply to the actual implementation of the national sub-projects. 

The applications will open on 1 December 2022 and will be administered by the NHMRC. The maximum grant is $300,000 with funding expected to be available from June 2023. The Guidelines are available on Grant Connect here.